ES2162908T3 - Derivados de la proteina-1 quimioatractora de monocitos (mcp-1) humana. - Google Patents

Derivados de la proteina-1 quimioatractora de monocitos (mcp-1) humana.

Info

Publication number
ES2162908T3
ES2162908T3 ES95902480T ES95902480T ES2162908T3 ES 2162908 T3 ES2162908 T3 ES 2162908T3 ES 95902480 T ES95902480 T ES 95902480T ES 95902480 T ES95902480 T ES 95902480T ES 2162908 T3 ES2162908 T3 ES 2162908T3
Authority
ES
Spain
Prior art keywords
mcp
derivatives
substituted
monocyte chemoattractant
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902480T
Other languages
English (en)
Inventor
Barrett Rollins
Yu Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2162908T3 publication Critical patent/ES2162908T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN DERIVADO DE LA MCP-1 Y A COMPOSICIONES FARMACEUTICAS DEL MISMO, EN DONDE LA MCP-1 HUMANA HA SIDO MODIFICADA DE MANERA QUE LA PROTEINA INHIBA LA ACTIVIDAD QUIMIOATRAYENTE DE LOS MONOCITOS. SE HA ENCONTRADO UNA INHIBICION AFORTUNADA DE LA ACTIVIDAD EN DONDE LA MCP-1 SE MODIFICA EN UNO O MAS DE LO SIGUIENTE: A) LA 28-TIROSINA SE SUSTITUYE POR ASPARTATO, B) LA 24-ARGININA SE SUSTITUYE POR FENILANINA, C) EL 3-ASPARTATO SE SUSTITUYE POR ALANINA, Y/O D) SE ELIMINA LA SECUENCIA DE AMINOACIDO 2-8. LOS DERIVADOS DE LA MCP-1 PRESENTADOS PUEDEN ADMINISTRARSE A UN PACIENTE QUE NECESITE LA INHIBICION DE LA ACTIVIDAD QUIMIOATRAYENTE DE LOS MONOCITOS DE LA MCP-1. POR EJEMPLO, LOS DERIVADOS PUEDEN UTILIZARSE PARA PREVENIR LA RESTENOSIS, TAL COMO LA QUE ES COMUN EN UN PACIENTE QUE SUFRA DE ANGIOPLASTIA DE LAS ARTERIAS CORONARIAS. LA INVENCION SE REFIERE ADEMAS A COMPOSICIONES Y METODOS PARA INHIBIR LA ACTIVIDAD QUIMIOATRAYENTE DE LOS MONOCITOS DE LA MCP-1 QUE EMPLEAN LOS DERIVADOS DESCRITOS.
ES95902480T 1993-11-12 1994-11-07 Derivados de la proteina-1 quimioatractora de monocitos (mcp-1) humana. Expired - Lifetime ES2162908T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15230193A 1993-11-12 1993-11-12

Publications (1)

Publication Number Publication Date
ES2162908T3 true ES2162908T3 (es) 2002-01-16

Family

ID=22542340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902480T Expired - Lifetime ES2162908T3 (es) 1993-11-12 1994-11-07 Derivados de la proteina-1 quimioatractora de monocitos (mcp-1) humana.

Country Status (10)

Country Link
US (1) US5459128A (es)
EP (1) EP0725794B1 (es)
JP (3) JP4040083B2 (es)
AT (1) ATE204583T1 (es)
CA (1) CA2176217A1 (es)
DE (1) DE69428049T2 (es)
DK (1) DK0725794T3 (es)
ES (1) ES2162908T3 (es)
PT (1) PT725794E (es)
WO (1) WO1995013295A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
WO1994029341A1 (en) * 1993-06-08 1994-12-22 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
US5663450A (en) * 1993-08-17 1997-09-02 Cv Therapeutics Macrophage lipid chemoattractant
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
EP0740701B1 (en) * 1994-01-13 2006-12-06 The Regents of the University of California Mammalian monocyte chemoattractant protein receptors
US6100389A (en) * 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US6491906B1 (en) 1995-06-01 2002-12-10 The Regents Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US7265083B2 (en) 1995-06-06 2007-09-04 The Regents Of The University Of Michigan Treatment of idiopathic pulmonary fibrosis using IP-10
US6790947B1 (en) 1995-06-07 2004-09-14 Icos Corporation Polynucleotides encoding macrophage derived chemokine
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US5688927A (en) * 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
JPH10507646A (ja) * 1995-06-07 1998-07-28 アイコス コーポレイション マクロファージ由来ケモカインおよびケモカインアナログ
US6320023B1 (en) 1995-06-07 2001-11-20 Icos Corporation Macrophage derived chemokine
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6274342B1 (en) 1996-09-18 2001-08-14 Center For Blood Research, Inc. Nucleic acid molecules encoding monocyte chemotactic protein 5 (MCP-5) molecules and uses therefor
US6673915B1 (en) 1996-09-30 2004-01-06 General Hospital Corporation Nucleic acid encoding monocyte chemotactic protein 4
WO1998014573A1 (en) * 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
JP4712975B2 (ja) * 1999-01-12 2011-06-29 ケンブリッジ エンタープライズ リミティド 炎症反応を阻害又は増強するための組成物及び方法
AU2001258836A1 (en) * 2000-05-26 2001-12-03 Kensuke Egashira Preventives and remedies for pulmonary hypertension
EP1325751A4 (en) 2000-10-11 2005-05-04 Daiichi Seiyaku Co NEW MEDICAMENTS FOR THE TREATMENT OF LIVER DISEASES
US6902914B2 (en) * 2001-09-28 2005-06-07 Sigma-Aldrich, Co. Recombinant DNA processes using a dNTP mixture containing modified nucleotides
US20040116341A1 (en) * 2001-10-23 2004-06-17 Holtzman Michael J. Methods for ameliorating childhood infections
US7541139B2 (en) * 2002-06-28 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
ATE394676T1 (de) * 2003-03-12 2008-05-15 Rappaport Family Inst For Res Verbindungen und verfahren zur diagnose von prostatakrebs
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
CN101443357A (zh) * 2005-08-12 2009-05-27 先灵公司 Mcp1融合物
US20100166733A1 (en) * 2006-06-21 2010-07-01 Zurit Levin Mcp-1 splice variants and methods of using same
US9855370B2 (en) * 2008-01-08 2018-01-02 Yale University Compositions and methods for promoting patency of vascular grafts
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
CA3007631A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Optimized patient specific non-linear tissue engineered vascular grafts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168051A (en) * 1985-03-22 1992-12-01 Genentech, Inc. Nucleic acid encoding TGF-β its uses
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease

Also Published As

Publication number Publication date
CA2176217A1 (en) 1995-05-18
US5459128A (en) 1995-10-17
EP0725794A1 (en) 1996-08-14
DE69428049T2 (de) 2002-04-18
JPH09505053A (ja) 1997-05-20
PT725794E (pt) 2002-02-28
DE69428049D1 (de) 2001-09-27
JP2008007520A (ja) 2008-01-17
DK0725794T3 (da) 2001-12-10
ATE204583T1 (de) 2001-09-15
JP2006225402A (ja) 2006-08-31
EP0725794B1 (en) 2001-08-22
JP4040083B2 (ja) 2008-01-30
WO1995013295A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
ES2162908T3 (es) Derivados de la proteina-1 quimioatractora de monocitos (mcp-1) humana.
DK0910647T3 (da) Human DNase i hyperaktive varianter
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
MX9206008A (es) Inhibidores de enzima proteolitica, derivados de sacarina 2-substituida.
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
NO940809L (no) Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist
FI951454A (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
ATE245977T1 (de) Therapeutische substituierte guanidine
MY106067A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors.
FI951298A (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
MX9307983A (es) Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c.
ES2057544T3 (es) Composiciones estabilizadas a base de fgf.
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
PT652900E (pt) Inibidores da trombina
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
DK0811068T3 (da) Humane DNase I varianter
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ES2160102T3 (es) Tratamiento del eritema provocado por uv.
ATE139702T1 (de) Die freisetzung des histamin hemmenden faktors sowie diesen enthaltende präparate
ES2104416T3 (es) Glicosilamidas de 2-aminoacilamino-2-desoxi-azucares.
MA23755A1 (fr) Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 725794

Country of ref document: ES